Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Baxter
Moodys
Medtronic
Dow
Johnson and Johnson
Boehringer Ingelheim
Covington
Cipla

Generated: May 26, 2018

DrugPatentWatch Database Preview

Belinostat - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for belinostat and what is the scope of belinostat patent protection?

Belinostat
is the generic ingredient in one branded drug marketed by Spectrum Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Belinostat has fifty-nine patent family members in twenty-seven countries.

There are four drug master file entries for belinostat. One supplier is listed for this compound.
Summary for belinostat
International Patents:59
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 4
Suppliers / Packagers: 1
Bulk Api Vendors: 67
Clinical Trials: 41
Patent Applications: 19
DailyMed Link:belinostat at DailyMed
Pharmacology for belinostat
Synonyms for belinostat
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
(E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid
(E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide
(E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide
(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-
2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-
2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-
2-Propenamide,N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-,(2E)-
414864-00-9
5OG
866323-14-0
866323-14-0 (E Isomer)
A25012
AB0007889
ABP000140
AC-25046
AKOS025401741
AN-1073
AOB87787
API0003555
AS-17068
AX8144528
BC251660
BCP9000386
BCPP000351
BDBM25150
Beleodaq
Beleodaq (TN)
Belinostat (PXD101)
Belinostat - PXD101
Belinostat (PXD101)
Belinostat [USAN:INN]
Belinostat Ph3
Belinostat,PXD101, PX105684
Belinostat/PXD101,PX105684/
BRD-K17743125-001-01-9
CCG-208758
CHEBI:61076
CHEBI:94531
D0XT6W
DB05015
DTXSID60194378
E-Belinostat
EX-A180
F4H96P17NZ
GTPL7496
J-523584
KB-74881
LS41098
MFCD08064035
MLS006011091
MolPort-009-679-433
N-Hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide
N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide
N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide
N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE
N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide
N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide
N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamide
N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PR
N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE
NCNRHFGMJRPRSK-MDZDMXLPSA-N
NSC-726630
NSC726630
OR190689
PDX-101
PDX101
PubChem22405
PX 105684
PX-105684
PX105684
PX105684, 414864-00-9
PXD 101
PXD-101
PXD101
QCR-181
RL03602
RT-014445
s1085
SC-71101
SMR004702879
UNII-F4H96P17NZ
W-5363
ZINC3818726

US Patents and Regulatory Information for belinostat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Spectrum Pharms BELEODAQ belinostat POWDER;IV (INFUSION) 206256-001 Jul 3, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Spectrum Pharms BELEODAQ belinostat POWDER;IV (INFUSION) 206256-001 Jul 3, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Spectrum Pharms BELEODAQ belinostat POWDER;IV (INFUSION) 206256-001 Jul 3, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Spectrum Pharms BELEODAQ belinostat POWDER;IV (INFUSION) 206256-001 Jul 3, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for belinostat

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,557,140 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
7,183,298 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
9,856,211 Pharmaceutical formulations of HDAC inhibitors ➤ Sign Up
7,407,988 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Argus Health
Moodys
Mallinckrodt
Chubb
Express Scripts
Cantor Fitzgerald
Fuji
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.